4 months ago
BMRN
AnalystsMitchell S. KapoorMitchell S. Kapoor's Stock Forecasts
AnalystsMitchell S. Kapoor
Sectors:
Industries:
Analyst Ranking
Top 12%
#624 out of 5206 analysts
Average Return
+17.19%
Win Rate
54%38 out of 71
Risk vs Reward
Poor
Good
Mitchell S. Kapoor's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Alumis IncALMS | +576.99% | $4.39 | $29.72 | 2025-08-14 - 2026-03-02 | Buy |
Tyra Biosciences IncTYRA | +177.71% | $11.71 | $32.52 | 2025-08-22 - 2026-03-02 | Buy |
Alumis IncALMS | +168.72% | $11.06 | $29.72 | 2025-12-18 - 2026-03-02 | Buy |
Kyverna Therapeutics IncKYTX | +129.38% | $3.71 | $8.51 | 2025-08-29 - 2026-03-02 | Buy |
Oruka Therapeutics IncORKA | +120.92% | $15.25 | $33.69 | 2025-08-18 - 2026-03-02 | Buy |
Mitchell S. Kapoor Analyst Color
Get additional color on Mitchell S. Kapoor's coverage of popular stocks
6 months ago
BMRN
Mitchell S. Kapoor's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Crescent Biopharma IncCBIO | 3 | Buy | $22.00 | +96.43% | Maintains | 2 days ago |
Sarepta Therapeutics IncSRPT | 4 | Sell | $5.00 | -69.36% | Reiterates | 2 days ago |
Biomarin Pharmaceutical IncBMRN | 5 | Hold | $55.00 | -7.93% | Reiterates | 2 days ago |
Summit Therapeutics IncSMMT | 8 | Buy | $30.00 | +85.30% | Maintains | 8 days ago |
Tyra Biosciences IncTYRA | 2 | Buy | $45.00 | +38.38% | Maintains | 15 days ago |
Incyte CorpINCY | 2 | Buy | $135.00 | +34.95% | Reiterates | 21 days ago |
Evommune IncEVMN | 2 | Buy | $65.00 | +153.81% | Maintains | 21 days ago |
Korro Bio IncKRRO | 2 | Buy | $20.00 | +73.91% | Upgrades | a month ago |
Intellia Therapeutics IncNTLA | 6 | Buy | $25.00 | +61.92% | Maintains | a month ago |
Legend Biotech CorpLEGN | 2 | Buy | $50.00 | +171.15% | Maintains | a month ago |
Avalo Therapeutics IncAVTX | 2 | Buy | $25.00 | +39.04% | Reiterates | 2 months ago |
Neurogene IncNGNE | 4 | Buy | $70.00 | +237.51% | Reiterates | 2 months ago |
Lexeo Therapeutics IncLXEO | 4 | Buy | $10.00 | +40.25% | Maintains | 2 months ago |
Alumis IncALMS | 3 | Buy | $40.00 | +34.59% | Reiterates | 2 months ago |
Halozyme Therapeutics IncHALO | 5 | Buy | $90.00 | +28.85% | Reiterates | 2 months ago |
Lyell Immunopharma IncLYEL | 2 | Buy | $45.00 | +86.72% | Upgrades | 3 months ago |
Meiragtx Holdings PLCMGTX | 1 | Buy | $20.00 | +163.85% | Initiates Coverage On | 3 months ago |
Cartesian Therapeutics IncRNAC | 1 | Buy | $30.00 | +294.74% | Maintains | 3 months ago |
Cytomx Therapeutics IncCTMX | 1 | Buy | $10.00 | +87.27% | Maintains | 4 months ago |
Ionis Pharmaceuticals IncIONS | 6 | Buy | $110.00 | +34.21% | Maintains | 4 months ago |
Kyverna Therapeutics IncKYTX | 2 | Buy | $20.00 | +135.02% | Maintains | 4 months ago |
Oruka Therapeutics IncORKA | 2 | Buy | $40.00 | +18.73% | Maintains | 4 months ago |
Crispr Therapeutics AgCRSP | 1 | Buy | $80.00 | +31.64% | Reiterates | 5 months ago |
Instil Bio IncTIL | 3 | Buy | $125.00 | +1,356.88% | Reiterates | 6 months ago |
Editas Medicine IncEDIT | 2 | Buy | $5.00 | +132.56% | Reiterates | 6 months ago |
Metagenomi IncMGX | 1 | Buy | $7.00 | +357.52% | Reiterates | 6 months ago |
Zura Bio LtdZURA | 1 | Hold | $2.00 | -70.41% | Maintains | 6 months ago |
Boundless Bio IncBOLD | 1 | Buy | $4.00 | +244.83% | Maintains | 7 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.